Article
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
Blood - 4 Nov 2010
Alchalby Haefaa, Badbaran Anita, Zabelina Tatjana, Kobbe Guido, Hahn Joachim, Wolff Daniel, Bornhäuser Martin, Thiede Christian, Baurmann Herrad, Bethge Wolfgang, Hildebrandt York, Bacher Ulrike, Fehse Boris, Zander Axel R, Kröger Nicolaus
Abstract excerpt
Allogeneic stem cell transplantation (ASCT) after reduced-intensity conditioning has become a reasonable treatment option for patients with advanced myelofibrosis. The role of characteristic molecular genetic abnormalities, such as JAK2V617F on outcome of ASCT, is not yet elucidated. In 139 of 162 myelofibrosis patients with known JAK2V617F mutation status who received ASCT after reduced-intensity conditioning,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
